1. MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells

   Stutvoet, T. S., Kol, A., de Vries, E. G. E., de Bruyn, M., Fehrmann, R. S. N., van Scheltinga, A. G. T. T. & de Jong, S., Sep-2019, In : JOURNAL OF PATHOLOGY. 249, 1, p. 52-64 13 p.

   Research output: Contribution to journal › Article › Academic › peer-review

2. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma

   Caumanns, J. J., van Wijngaarden, A., Kol, A., Meersma, G. J., Jalving, M., Bernards, R., van der Zee, A. G. J., Wisman, G. B. A. & de Jong, S., 2019, In : Cancer letters. 461, p. 102-111 10 p.

   Research output: Contribution to journal › Article › Academic › peer-review

3. MAPK pathway activity plays a key role in programmed death ligand-1 expression of EGFR wild-type non-small cell lung adenocarcinoma cells

   Stutvoet, T., Kol, A., de Vries, E., de Bruyn, M., Fehrmann, R., van Scheltinga, A. T. & de Jong, S., Nov-2018, p. E78-E79. 2 p.

   Research output: Contribution to conference › Poster › Academic

4. A transcriptionally distinct CXCL13+CD103+CD8+ T-cell population is associated with B-cell recruitment and neoantigen load in human cancer

   Workel, H. H., Lubbers, J. M., Arnold, R., Prins, T. M., van der Vlies, P., de Lange, K., Bosse, T., Van Gool, I. C., Eggink, F. A., Wouters, M. C., Komdeur, F. L., van der Slikke, E. C., Creutzberg, C. L., Kol, A., Plat, A., Glaire, M., Church, D. N., Nijman, H. W. & de Bruyn, M., May-2019, In : Cancer immunology research. 7, 5, p. 784-796 13 p.

   Research output: Contribution to journal › Article › Academic › peer-review

5. Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy

   Kol, K. J-D., 2019, [Groningen]: Rijksuniversiteit Groningen. 175 p.

   Research output: Thesis › Thesis fully internal (DIV) › Academic

View all (11) »